Dyadic regains compliance with Nasdaq listing rules
Dyadic International, Inc. reported that Nasdaq confirmed the company has regained compliance with Nasdaq Listing Rules 5550(a)(2) and 5550(b).
Rhea-AI Filing Summary
Dyadic International, Inc. reported that Nasdaq confirmed the company has regained compliance with Nasdaq Listing Rules 5550(a)(2) and 5550(b). As a result, Dyadic’s common stock will continue to be listed and traded on The Nasdaq Capital Market.
Management characterizes the resolution of the listing matter as providing greater stability and reiterates its focus on executing its business strategy, including developing and commercializing its own products, expanding adoption of its C1 and Dapibus™ protein production platforms, advancing strategic collaborations and pursuing long-term shareholder value.
Positive
- Nasdaq confirms regained compliance and continued listing: Dyadic has regained compliance with Nasdaq Listing Rules 5550(a)(2) and 5550(b), and its common stock will continue to be listed and traded on The Nasdaq Capital Market.
Negative
- None.
8-K Event Classification
Key Figures
Key Terms
Nasdaq Listing Rules 5550(a)(2) and 5550(b) regulatory
The Nasdaq Capital Market market
forward-looking statements regulatory
Risk Factors financial
protein production platforms technical
FAQ
What did Dyadic International (DYAI) announce about its Nasdaq listing?
Which Nasdaq Listing Rules did Dyadic (DYAI) regain compliance with?
Does Dyadic International’s (DYAI) stock remain on The Nasdaq Capital Market?
What business focus did Dyadic (DYAI) highlight in its announcement?
What markets does Dyadic Applied BioSolutions (DYAI) target with its protein platforms?
What forward-looking risks does Dyadic (DYAI) reference in this announcement?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
| (State
or other jurisdiction of incorporation or organization) |
(Commission File Number) |
(I.R.S.
Employer Identification Number) |
(Address of principal executive offices and zip code)
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| The
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01. Other Events.
On July 24, 2026, Dyadic International, Inc. (the “Company”) issued a press release announcing that the Nasdaq Stock Market LLC (“Nasdaq”) confirmed that the Company has regained compliance with Nasdaq Listing Rules 5550(a)(2) and 5550(b), and that the Company’s common stock will continue to be listed and traded on the Nasdaq Capital Market. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit Number |
Description | |
| 99.1 | Press Release of Dyadic International, Inc., dated July 24, 2026. | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |
| 2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: July 24, 2026 | DYADIC INTERNATIONAL, INC. | |
| By: | /s/ Ping Rawson | |
| Name: | Ping Rawson | |
| Title: | Chief Financial Officer | |
| 3 |
Exhibit 99.1
Dyadic Announces Continued Listing on The Nasdaq Capital Market
JUPITER, Fla., July 24, 2026 — Dyadic International, Inc. (Nasdaq: DYAI) (“Dyadic” or the “Company”), d/b/a Dyadic Applied BioSolutions, a biotechnology company developing recombinant protein solutions across the life sciences, food and nutrition, bio-industrial and biopharmaceutical markets, today announced that Nasdaq has confirmed that the Company has regained compliance with Nasdaq Listing Rules 5550(a)(2) and 5550(b). The Company’s common stock continues to be listed and traded on The Nasdaq Capital Market.
“We are pleased that the Nasdaq continued listing matter has been resolved and that Dyadic’s common stock will continue to be listed on Nasdaq,” said Mark Emalfarb, Chief Executive Officer of Dyadic. “With this greater stability regarding our Nasdaq listing, we remain focused on executing our business strategy, developing and commercializing our own products, expanding the commercial adoption of our C1 and Dapibus™ protein production platforms, advancing strategic collaborations and creating long-term shareholder value.”
About Dyadic Applied BioSolutions
Dyadic Applied BioSolutions is a global biotechnology company that aims to develop and commercialize scalable, non-animal protein production platforms to meet growing global demand across the life sciences, food and nutrition, and bio-industrial markets. These high-value proteins are designed to enable customers to develop more efficient, scalable and sustainable products. Dyadic’s proprietary Dapibus™ and C1 expression systems support rapid, cost-effective and flexible manufacturing.
For more information, please visit www.dyadic.com.
Safe Harbor Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), including statements regarding Dyadic International’s expectations, intentions, strategies and beliefs pertaining to future events or future financial performance, such as the success of our clinical trial and interest in our protein production platforms, our research projects and third-party collaborations, as well as the availability of necessary funding. Forward-looking statements generally can be identified by use of the words “expect,” “should,” “intend,” “anticipate,” “will,” “project,” “may,” “might,” “potential” or “continue,” and other similar terms or variations thereof. Dyadic International, Inc. and its subsidiaries caution readers that any forward-looking information is not a guarantee of future performance and that actual results could differ materially from those contained in the forward-looking information. Such statements reflect the current views of our management with respect to our operations, results of operations and future financial performance. Forward-looking statements involve many risks, uncertainties or other factors beyond Dyadic’s control. These factors include, but are not limited to: (i) our history of net losses; (ii) market and regulatory acceptance of our microbial protein production platforms and other technologies; (iii) failure to commercialize our microbial protein production platforms or our other technologies; (iv) competition, including from alternative technologies; (v) the results of nonclinical studies and clinical trials; (vi) our capital needs; (vii) changes in global economic and financial conditions; (viii) our reliance on information technology; (ix) our dependence on third parties; (x) government regulations and environmental, social and governance issues; (xi) intellectual property risks; (xii) our ability to comply with the listing standards of The Nasdaq Stock Market LLC; and (xiii) other factors discussed in Dyadic’s publicly available filings, including information set forth under the caption “Risk Factors” in Dyadic’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 25, 2026, as amended on April 30, 2026, and Quarterly Report on Form 10-Q filed with the SEC on May 13, 2026, as such factors may be updated from time to time in Dyadic’s periodic filings with the SEC, which are accessible on the SEC’s website and at www.dyadic.com. The forward-looking statements contained in this press release are made only as of the date hereof, and except as required by law, we undertake no obligation to publicly update any forward-looking statements for any reason after the date of this press release to conform these statements to actual results or to changes in our expectations.
Media Contact:
Dyadic Applied BioSolutions
Ping Rawson
Chief Financial Officer
Phone: (561) 743-8333
Email: ir@dyadic.com